Von hippel-lindau disease: Genetic and clinical observations

Frontiers of Hormone Research

Volumn 28, Issue , 2001, Pages 131-166

  Iliopoulos, Othon ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE; PEPTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ADRENAL TUMOR; BRAIN TUMOR; GENETICS; HEMANGIOBLASTOMA; HUMAN; KIDNEY TUMOR; METABOLISM; MUTATION; PHEOCHROMOCYTOMA; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; BRAIN NEOPLASMS; GENES, TUMOR SUPPRESSOR; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; MUTATION; PEPTIDE SYNTHASES; PHEOCHROMOCYTOMA; SKP CULLIN F-BOX PROTEIN LIGASES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0035231908     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061052     Document Type: Article

References (222)

1. McKusick VA: Mendelian Inheritance in Man. Baltimore, Johns Hopkins University Press, 1992.
2. Collins ET: Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK 1894;14:141-149.
3. von Hippel E: Ueber eine sehr seltene Erkrankung der Netzhaut. Graefes Arch Ophthalmol 1904;59:83-106.
4. Lindau A: Zur Frage der Angiomatosis Retinae und ihrer Hirnkomplikation. Acta Ophthalmol 1927;4:193-226.
5. Melmon K, Rosen S: Lindau's disease. Am J Med 1964;36:595-617.
6. Fulton JF: Harvey Gushing: A Biography. Springfield, Charles C. Thomas, 1946.
7. Grossniklaus H, Thomas J, Vigneswaran N, Jarrett WH: Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation. Ophthalmology 1992;99:140-145.
8. Lamiell J, Salazar F, Hsia Y: von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989;68:1-29.
9. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
10. Maddock I, Moran A, Maher E, Teare M, Norman A, Payne S, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans D: A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120-127.
11. Filling-Katz M, Choyke P, Oldfield E, Charnas L, Patronas N, Glenn G, Gorin M, Morgan J, Linehan W, Seizinger BR, et al: Central nervous system involvement in von Hippel-Lindau disease. Neurology 1991;41:41-46.
12. Wizigmann-Voos S, Plate KH: Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol 1996;11:1049-1061.
13. Omulecka A, Lach B, Alwasiak J, Gregor A: Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. Folia Neuropathol 1995;33:41-50.
14. Richard S, Campello C, Taillandier L, Parker F, Resche F: Hemangioblastoma of the central nervous system in von Hippel-Lindau disease. J Intern Med 1998;243:547-553.
15. Richard S, David P, Marsot-Dupuch K, Giraud S, Beroud C, Resche F: Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev 2000;23:1-22.
16. Bakshi R, Mechtler LL, Patel MJ, Lindsay BD, Messinger S, Gibbons KJ: Spinal leptomeningeal hemangioblastomatosis in von Hippel-Lindau disease: Magnetic resonance and pathologic findings. J Neuroimaging 1997;7:242-244.
17. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B: von Hippel-Lindau disease: Genetic, clinical and imaging features. Radiology 1995;194:629-642.
18. Giannini C, Scheithauer BW, Hellbusch LC, Rasmussen AG, Fox MW, McCormock SR, Davis DH: Peripheral nerve hemangioblastoma. Mol Pathol 1998;11:999-1004.
19. Roessler K, Dietrich W, Haberler C, Goerzer H, Czech T: Multiple spinal 'miliary' hemangioblastomas in von Hippel-Lindau (vHL) disease without cerebellar involvement. A case report and review of the literature. Neurosurg Rev 1999;22:130-134.
20. Rojiani AM, Owen DA, Berry K, Woodhurst B, Anderson FH, Scudamore CH, Erb S: Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. Am J Surg Pathol 1991;15:81-86.
21. Richard S, Beigelman C, Gerber S, Van Effenterre R, Gaudric A, Sahel M, et al: L'hémangioblastome existe-t-il en dehors de la maladie de von Hippel-Lindau? Neurochirurgie 1994;40:145-154.
22. Sharma RR, Cast IP, O'Brien C: Supratentorial haemangioblastoma not associated with von Hippel-Lindau complex or polycythaemia: Case report and literature review. Br J Neurosurg 1995;9:81-84.
23. Wittebol-Post D, Hes FJ, Lips CJM: The eye in von Hippel-Lindau disease. Long term follow up of screening and treatment recommendations. J Intern Med 1998;243:555-561.
24. Maher E, Kaelin WG: von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-391.
25. Niemela M, Lemeta S, Summanen P, Bohling T, Sainio M, Kere J, Poussa K, Sankila R, Haapasalo H, Kaariainen H, Pukkala E, Jaaskelainen J: Long term prognosis of haemangioblastoma of the CNS: Impact of von Hippel-Lindau disease. Acta Neurochir (Wien) 1999;141:1147-1156.
26. Horton JC, Harsh GR 4th, Fisher JW, Hoyt WF: von Hippel-Lindau disease and erythrocytosis: Radioimmunoassay of erythropoietin in cyst fluid from a brainstem hemangioblastoma. Neurology 1991;41:753-754.
27. Krieg M, Marti HH, Plate KH: Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998;92:3388-3393.
28. Chang SD, Meisel JA, Hancock SL, Martin DP, McManus M, Adler JR: Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery 1998;43:28-34.
29. Niemela M, Lim YJ, Soderman M, Jaaskelainen J, Lindquist C: Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg 1996;85:591-596.
30. Patrice SJ, Sneed PK, Flickinger JC, Shrieve DC, Pollock BE, Alexander E, Larson DA, Kondziolka DS, Gutin PH, Wara WM, McDermott MW, Lunsford LD, Loeffler JS: Radiosurgery for hemangioblastoma: Results of a multiinstitutional experience. Int J Radial Oncol Biol Phys 1996;35:493-499.
31. Malek RS, Omess PJ, Benson RC Jr, Zincke H: Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med 1987;82:236-238.
32. Choyke P, Glenn G, Walther M, Zbar B, Weiss G, Alexander RB, Hayes W, Long J, Thakore K, Linehan W: The natural history of renal lesions in von Hippel-Lindau disease: A serial CT study in 28 patients. AJR Am J Roentgenol 1992;159:1229-1234.
33. Richard S, Chauveau D, Chretien Y, Beigelman C, Denys A, Fendler J, Fromont G, Paraf F, Helenon O, Nizard S, Proye C, Resche F, Plouin P-F: Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol Necker Hosp 1994;23:1-27.
34. Kragel PJ, Walther MM, Pestaner JP, Filling-Katz MR: Simple renal cysts, atypical renal cysts and renal cell carcinoma in von Hippel-Lindau disease: A lectin and immunohistochemical study in six patients. Mod Pathol 1991;4:210-214.
35. Nelson JB, Oyasu R, Dalton DP: The clinical and pathological manifestations of renal tumors in von Hippel-Lindau disease. J Urol 1994;156:2221-2226.
36. Solomon D, Schwartz A: Renal pathology in von Hippel-Lindau disease. Hum Pathol 1988;19:1072-1079.
37. Frydenberg M, Malek RS, Zincke H: Conservative renal surgery for renal cell carcinoma in von Hippel-Lindau's disease. J Urol 1993;149:461-464.
38. McClellan MW, Choyke P, Weiss G, Manolatos C, Long J, Reiter R, Alexander RB, Linehan WM: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 1995;153:913-916.
39. Steinbach F, Novick A, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB, Marshall F, Marsh C: Treatment of renal cell carcinoma in von Hippel-Lindau disease: A multicenter study. J Urol 1995;153:1812-1816.
40. Goldfarb DA: Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. J Intern Med 1998;243:563-567.
41. Zbar B, Kaelin W, Maher E, Richard S: Third International Meeting on von Hippel-Lindau disease. Cancer Res 1999;59:2251-2253.
42. Bender BU, Altehofer C, Januszewicz A, Gartner R, Schmidt H, Hoffmann MM, Heidemann PH, Neumann HP: Functioning thoracic paraganglioma: Association with von Hippel-Lindau syndrome. J Clin Endocrinol Metab 1997;82:3356-3360.
43. Chen F, Slife L, Kishida T, Mulvihill S, Tisherman E, Zbar B: Genotype-phenotype correlation in von Hippel-Lindau disease: Identification of a mutation associated with VHL type 2A. J Med Genet 1996;33:716-717.
44. Maher E, Webster A, Richards F, Green J, Crossey P, Payne S, Moore A: Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J Med Genet 1996;33:328-332.
45. Neumann H, Bender B: Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998;243:541-545.
46. Martin R, Hockey A, Walpole I, Goldblatt J: Variable penetrance of familial pheochromocytoma associated with the von Hippel-Lindau gene mutation, S68W. Mutations in brief no. 150. Online. Hum Mutat 1998;12:71.
47. Gross D, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D: Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 1996;81:147-149.
48. Ritter M, Frilling A, Crossey P, Hoppner W, Maher E, Mulligan L, Ponder B, Engelhardt D: Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 1996;81:1035-1037.
49. Eng C, Crossey P, Mulligan L, Healey C, Houghton C, Prowse A, Chew S, Dahia P, O'Riordan J, Toledo S, Smith D, Maher E, Ponder B: Mutations in the RET proto-oncogene and the von HippelLindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995;32:934-937.
50. Woodward E, Eng C, McMahon R, Voutilainen R, Affara N, Ponder B, Maher E: Genetic predisposition to phaeochromocytoma: Analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 1997;6:1051-1056.
51. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Farmer RJ, Volk B, Kirste G: Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531-1538.
52. Gagel RF: Pheochromocytoma, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1994;330:1090-1091.
53. Loh KC, Shlossberg AH, Abbott EC, Salisbury SR, Tan MH: Phaeochromocytoma: A ten-year survey. QJM 1997;90:51-60.
54. Walther MM, Herring J, Choyke PL, Linehan WM: Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. J Urol 2000;164:14-17.
55. Neumann HP, Reincke M, Bender BU, Eisner R, Janetschek G: Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999;84:2608-2610.
56. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR: Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999;340:1872-1879.
57. Binkovitz L, Johnson C, Stephens D: Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 1990;155:501-505.
58. Hough DM, Stephens DH, Johnson CD, Binkovitz LA: Pancreatic lesions in von Hippel-Lindau disease: Prevalence, clinical significance and CT findings. AJR Am J Roentgenol 1994;162:1091-1094.
59. Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, Sigmund G, Riegler P, Haag K, Schollmeyer P, et al: Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 1991;101:465-471.
60. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z: Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: Histopathological and molecular genetic analysis. Am J Pathol 1998;153:223-231.
61. Fishman RS, Bartholomew LG: Severe pancreatic involvement in three generations in von HippelLindau disease. Mayo Clin Proc 1979;54:329-331.
62. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan WM, Oldfield EH: Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997;277:1461-1466.
63. Megerian CA, McKenna MJ, Nuss RC, Maniglia AJ, Ojemann RG, Pilch BZ, Nadol JB Jr: Endolymphatic sac tumors: Histopathologic confirmation, clinical characterization and implication in von Hippel-Lindau disease. Laryngoscope 1995;105:801-808.
64. Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, Linehan WM, Walther MM: Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997;49:926-931.
65. Karsdorp N, Elderson A, Wittebol-Post D, et al: von Hippel-Lindau disease: New strategies in early detection and treatment. Am J Med 1994;97:158-168.
66. Korn WT, Schatzki SC, DiSciullo AJ, Scully RE: Papillary cystadenoma of the broad ligament in von Hippel-Lindau disease. Am J Obstet Gynecol 1990;163:596-598.
67. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM, Collins D, Majoor-Krakauer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R, Oostra B, Aronin N, Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE, Gusella JF: von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-269.
68. Crossey P, Maher E, Jones M, Richards F, Latif F, Phipps M, Lush M, Foster K, Tory K, Green J, Oostra B, Yates J, Linehan W, Affara N, Lerman M, Zbar B, Nakamura Y, Ferguson-Smith M: Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum Mol Genet 1993;2:279-282.
69. Maher E, Bentley E, Yates J, Latif F, Lerman M, Zbar B, Affara N, Ferguson-Smith M: Localization of the gene for von Hippel-Lindau disease to a small region of chromosome 3p by genetic linkage analysis. Genomics 1991;10:957-960.
70. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan D-SR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Pasiler DL, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
71. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
72. Kuzmin I, Duh F-M, Latif F, Geil L, Zbar B, Lerman MI: Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 1995;10:2185-2194.
73. Renbaum P, Duh F-M, Latif F, Zbar B, Lerman M, Kuzmin I: Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene. Hum Genet 1996;98:666-671.
74. Kessler P, Vasavada S, Rackley R, Stackhouse T, Duh F, Latif F, Lerman M, Zbar B, Williams B: Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1995;1:457-466.
75. Nagashima Y, Miyagi Y, Udagawa K, Taki A, Misugi K, Sakai N, Kondo K, Kaneko S, Yao M, Shuin T: von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization. J Pathol 1996;180:271-274.
76. Richards F, Schofield P, Fleming S, Maher E: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-644.
77. Corless CL, Kibel A, Iliopoulos O, Kaelin WG Jr: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997;28:459-464.
78. Duan DR, Humphrey JS, Chen DYT, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, Klausner RD: Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995;92:6495-6499.
79. Gao J, Naglich JG, Laidlaw J, Whaley JM, Seizinger BR, Kley N: Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: Implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res 1995;55:743-747.
80. Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER: Comparative sequence analysis of the VHL tumor suppressor gene. Genomics 2000;65:253-265.
81. Adryan B, Decker H-J, Papas TS, Hsu T: Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 2000;19:2803-2811.
82. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DYT, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh F-M, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma (review). Biochim Biophys Acta 1996;1242:201-210.
83. Stolle C, Glenn G, Zbar B, Humphrey J, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan W: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
84. Vortmeyer A, Gnarra J, Emmert-Buck M, Katz D, Linehan W, Oldfield E, Zhuang Z: von HippelLindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997;28:540-543.
85. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149:2089-2094.
86. Zhuang Z, Bertheau P, Emmert-Buck M, Liotta L, Gnarra J, Linehan W, Lubensky I: A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 1995;146:620-625.
87. Goss KH, Groden J: Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000;18:1967-1979.
88. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM, Maher ER: Somatic mutations of the von HippelLindau disease tumor suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-2173.
89. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, Neumann HPH, Laidlaw J, Li FP, Klein-Szanto AJP, Seizinger BR, Kley N: Germ-line mutations in the von HippelLindau tumor suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 1994;55:1092-1102.
90. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-2855.
91. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan D-SR, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-9704.
92. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T, Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994;54:4845-4847.
93. Lee J-Y, Dong S-M, Park W-S, Yoo N-J, Kim C-S, Jang J-J, Chi J-G, Zbar B, Lubensky I, Linehan W, Vortmeyer A, Zhuang Z: Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998;58:504-508.
94. Oberstrass J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP: Mutations of the von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 1996;179:151-156.
95. Tse J, Wong J, Lo K-W, Poon W-S, Huang D, Ng H-K: Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 1997;107:459-466.
96. Prowse A, Webster A, Richards F, Richard S, Olschwang S, Resche F, Affara N, Maher E: Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-761.
97. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z: Allelic deletion and mutation of the von Hippel-Lindau tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 1997;151:951-956.
98. Hofstra RMW, Stelwagen T, Stulp RP, de Jong D, Hulsbeek M, Kamsteeg EJ, van den Berg A, Landsvater RM, Vermey A, Molenaar WM, Lips CJM, Buys CHCM: Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996;81:2881-2884.
99. Bender BU, Gutsche M, Gläsker S, Müller B, Kirste G, Eng C, Neumann HPH: Differential genetic alterations in sporadic and von Hippel-Lindau syndrome-associated pheochromocytomas. J Clin Endocrinol Metab 2000;85:4568-4574.
100. Bailly M, Bain C, Favrot M-C, Ozturk M: Somatic mutations of von Hippel-Lindau (VHL) tumor suppressor gene in European kidney cancers. Int J Cancer 1995;63:660-664.
101. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Lerman MI, Zbar B, Neumann HPH: von Hippel-Lindau disease with pheochromocytoma in the Black Forest region in Germany: Evidence for a founder effect. Hum Genet 1995;95:551-556.
102. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Ming HW, Schmidt L, Kaiman T, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 1995;5:66-75.
103. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER: Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-1308.
104. Glavac D, Neumann HPH, Wittke C, Jaening H, Masek O, Streicher T, Pausch F, Engelhardt D, Plate KH, Hofler H, Chen F, Zbar B, Brauch H: Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet 1996;98:271-280.
105. Richards F, Crossey P, Phipps M, Foster K, Latif F, Evans G, Sampson J, Lerman M, Zbar B, Affara N, Ferguson-Smith M, Maher E: Detailed mapping of germline deletions of the von HippelLindau disease tumour suppressor gene. Hum Mol Genet 1994;3:595-598.
106. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HPH, Tisherman S, Mulvihill JJ, Gross D, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CHM, Linehan MW, Lerman M: Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-357.
107. Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T: Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 1999;91:854-861.
108. Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 1999;284:455-461.
109. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, Walker S, Sutton R, Meltzer SJ, Field JK: Allelotype analysis of oesophageal adenocarcinoma: Loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-957.
110. Waber PG, Lee NK, Nisen PD: Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the von-Hippel-Lindau tumor suppressor gene in head and neck cancer. Oncogene 1996;12:365-369.
111. Sekido Y, Bader S, Latif F, Gnarra J, Gazdar A, Linchan W, Zbar B, Lerman M, Minna J: Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 1994;9:1599-1604.
112. Iliopoulos O, Kibel A, Gray S, Kaelin WG: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-826.
113. Iliopoulos O, Ohh M, Kaelin W: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-11666.
114. Schoenfeld A, Davidowitz E, Burk R: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA1998;95:8817-8822.
115. Blankenship C, Naglich JG, Whaley JM, Seizinger B, Kley N: Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-1535.
116. Iliopoulos O, Kaelin WG: The molecular basis of von Hippel-Lindau disease. Mol Med 1997;3:289-293.
117. Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis G, Klausner R: Transcriptiondependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999;19:1486-1497.
118. Groulx I, Bonicalzi M-E, Lee S: Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J Biol Chem 2000;275:8991-9000.
119. Kinzler K, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
120. Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 1998;280:1036-1037.
121. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B: Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 1995;55:4544-4548.
122. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 1996;93:10589-10594.
123. Pause A, Lee S, Lonergan KM, Klausner RD: The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998;95:993-998.
124. Aso T, Lane WS, Conaway JW, Conaway RC: Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II. Science 1995;269:1439-1443.
125. Duan DR, Pause A, Burgress W, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 1995;269:1402-1406.
126. Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG: Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-1446.
127. Garrett K, Siyun T, Bradsher J, Lane W, Conaway J, Conaway R: Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. Proc Natl Acad Sci USA 1994;91:5237-5241.
128. Garrett K, Aso T, Bradsher J, Foundling S, Lane W, Conaway R, Conaway J: Positive regulalion of general Iranscriplion faclor SIII by a tailed ubiquilin homolog. Proc Nail Acad Sci USA 1995;92:7172-7176.
129. Conaway R, Reines D, Garrell K, Powell W, Conaway J: Purificalion of RNA polymerase II general Iranscriplion factors from rat liver. Methods Enzymol 1996;273:194-207.
130. Aso T, Haque D, Barstead R, Conaway R, Conaway J: The inducible elongin A elongation activation domain: Structure, function and interaction with the elongin BC complex. EMBO J 1996;15:5557-5566.
131. Takagi Y, Conaway R, Conaway J: Characterization of elongin C functional domains required for interaction with elongin B and activation of elongin A. J Biol Chem 1996;271:1-7.
132. Kamura T, Sato S, Haque D, Liu L, Kaelin WJ, Conaway R, Conaway J: The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998;12:3872-3881.
133. Conaway JW, Kamura T, Conaway RC: The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta 1998;1377:M49-M54.
134. Conaway JW, Conaway R: Transcription elongation and human disease. Annu Rev Biochem 1999;68:301-319.
135. Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock EM: cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996;85:829-839.
136. Deshaies RJ: SCF and Cullin/RING H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999;15:435-467.
137. Schwob E, Böhm T, Mendenhall MD, Nasmyth K: The B-type cyclin inhibitor p40sicl controls the G1 to S transition in S. cerevisiae. Cell 1994;79:233-244.
138. Deshaies RJ, Cahu V, Kirschner M: Ubiquitination of the G1 cyclin cln2p by a Cdc34-dependent pathway. EMBO J 1995;14:303-312.
139. Jackson PK: Cell cycle: Cull and destroy. Curr Biol 1996;6:1209-1212.
140. Zachariae W, Shevchenko A, Andrews PD, Ciosk R, Galova M, Stark MJ, Mann M, Nasmyth K: Mass spectrometric analysis of the anaphase-promoting complex from yeast: Identification of a subunit related to cullins. Science 1998;279:1216-1219.
141. Lyapina SA, Correll CC, Kipreos ET, Deshaies RJ: Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. Proc Natl Acad Sci USA 1998;95:7451-7456.
142. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996;86:263-274.
143. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan Z-Q: Recruitment of a ROC1-CUL1 ubiquitin ligase by Skpl and HOS to catalyze the ubiquitination of IκBα. Cell 1999;3:527-533.
144. Seol JH, Feldman RM, Zachariae W, Shevchenko A, Correll CC, Lyapina S, Chi Y, Galova M, Claypool J, Sandmeyer S, Nasmyth K, Shevchenko A, Deshaies RJ: Cdc53/cullin and the essential Hrtl RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev 1999;13:1614-1626.
145. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W: p45SKP2 promotes p27Kipl degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-214.
146. Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998;95:11324-11329.
147. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199.
148. Marti A, Wirbelauer C, Scheffner M, Krek W: Interaction between ubiquitin-protein ligase SCF/ skp2andE2F1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14-19.
149. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y: Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998;396:590-594.
150. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW: The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and βcatenin and stimulates IκBα ubiquitination in vitro. Genes Dev 1999;13:270-283.
151. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z, Pan ZQ: The SCF(HOS/beta-TRCP)-ROC 1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000;20:1382-1393.
152. Lammer D, Mathias N, Laplaza JM, Jiang W, Liu Y, Callis J, Goebl M, Estelle M: Modification of yeast Cdc53p by the ubiquitin-related protein rublp affects function of the SCFCdc4 complex. Genes Dev 1998;12:914-926.
153. Osaka F, Kawasaki H, Aida N, Saeki M, Chiba T, Kawashima S, Tanaka K, Kalo S: A new NEDD8ligating system for cullin-4A. Genes Dev 1998;12:2263-2268.
154. Wada H, Yeh ET, Kamitani T: Identification of NEDD8-conjugation site in human cullin-2. Biochem Biophys Res Commun 1999;257:100-105.
155. Freed E, Lacey KR, Huie P, Lyapina SA, Deshaies RJ, Stearns T, Jackson PK: Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle. Genes Dev 1999;13:2242-2257.
156. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V: A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kipl by ubiquitination. Proc Natl Acad Sci USA 2000;97:4579-4584.
157. Furukawa M, Zhang Y, McCarville J, Ohta T, Xiong Y: The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1 Mol Cell Biol 2000;20:8185-8197.
158. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG: Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-741.
159. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Elledge SJ, Conaway RC, Harper JW, Conaway JW: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-661.
160. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW: The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999;13:2928-2933.
161. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-1833.
162. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
163. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:581-578.
164. Wang GL, Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-1237.
165. Huang LE, Gu J, Schau M, Bunn HF: Regulation of hypoxia-inducible factor 1α is mediated by an C>2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-7992.
166. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ: Activation of hypoxia-inducible factor-1: Definition and regulatory domains within the a subunit. J Biol Chem 1997;272:11205-11214.
167. Srinivas V, Zhang L-P, Zhu X-H, Caro J: Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor a (HIF1α) proteins. Biochem Biophys Res Commun 1999;260:557-561.
168. Semenza GL: HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. A Review. J Appl Physiol 2000;88:1474-1480.
169. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
170. Ryan HE, Lo L, Johnson RS: HIF1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-3015.
171. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L: p53 inhibits hypoxiainducible factor-stimulated transcription. J Biol Chem 1998;273:11995-11998.
172. Ravi R, Mookerjee B, Bhujwalla ZM, Sutler CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A: Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000;14:33-44.
173. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741.
174. Ohh M, Park CW, Ivan M, Huffman MA, Kirn TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427.
175. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-10435.
176. Mukhopadhyay D, Knebelmann B, Cohen H, Ananth S, Sukhatme V: The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-5639.
177. Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, Kishida T, Kaneko S, Yao M, Ohno S, Shuin T: Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-497.
178. Pal S, Claffey K, Cohen H, Mukhopadhyay D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272:27509-27512.
179. Pal S, Claffey K, Cohen H, Mukhopadhyay D: Activation of Spl-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 1998;273:26277-26280.
180. De Sepulveda P, Ilangumaran S, Rottapel R: Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem 2000;275:14005-14008.
181. Sato K, Terada K, Sugiyama T, Takahashi S, Saito M, Moriyama M, Kakinuma H, Suzuki Y, Kalo M, Kalo T: Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med 1994;173:355-360.
182. Takahashi A, Sasaki H, Kim S, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-4237.
183. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 1993;194:749-755.
184. Trimble M, Caro J, Talalla A, Brain M: Secondary erythrocytosis due to a cerebellar hemangioblastoma: Demonstration of erythropoietin mRNA in the tumor. Blood 1991;78:599-601.
185. Golde DW, Hocking WG: Polycythemia: Mechanisms and management. Ann Intern Med 1981;95:71-87.
186. Richard DE, Berra E, Pouyssegur J: Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-722.
187. Zhu H, Bunn HF: Oxygen sensing and signaling: Impact on the regulation of physiologically important genes. Respir Physiol 1999;115:239-247.
188. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-13340.
189. Goldberg MA, Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994;269:4355-4359.
190. Huang LE, Arany Z, Livingston DM, Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a subunit. J Biol Chem 1996;271:32253-32259.
191. Chandel NS, Van der Heiden MG, Thompson CB, Schumacker PT: Redox regulation of p53 during hypoxia. Oncogene 2000;19:3840-3848.
192. Iliopoulos O, Jiang C, Levy AP, Kaelin WG, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. ProcNatl Acad Sci USA 1996;93:10595-10599.
193. Wizigmann-Voos S, Breier G, Risau W, Plate K: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-1364.
194. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
195. Beelman CA, Parker R: Degradation of mRNA in eukaryotes. Cell 1995;81:179-183.
196. Jacobson A: Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem 1996;65:693-739.
197. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG, Goldberg MA: Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 1997;51:575-578.
198. Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 1996;271:25492-25497.
199. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor protein. Cancer Res 1998;58:226-231.
200. Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP: Transforming growth factor beta 1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999;59:2210-2216.
201. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
202. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
203. Ruoslahti E: Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999;76:1-20.
204. Pasqualini R, Bourdoulous S, Koivunen E, Woods VL Jr, Ruoslahti E: A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996;2:1197-1203.
205. Giancotti FG, Ruoslahti E: Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-859.
206. Vaheri A, Alitalo K, Hedman K, Keski-Oja J, Kurkinen M, Wartiovaara J: Fibronectin and the pericellular matrix of normal and transformed adherent cells. Ann NY Acad Sci 1978;312:343-353.
207. Wickner S, Maurizi MR, Gottesman S: Posttranslational quality control: Folding, refolding and degrading proteins. Science 1999;286:1888-1893.
208. Riezman H: The ins and outs of protein translocation. Science 1997;278:1728-1729.
209. Kaufman RK: Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211-1233.
210. Wu C, Keivens V, O'Toole T, McDonald J, Ginsberg M: Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell 1995;83:715-724.
211. Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I, Holbrook NJ: Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 1999;19:1289-1300.
212. Ivanov S, Kuzmin I, Wei M-H, Pack S, Geil L, Johnson B, Stanbridge E, Lerman M: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-12601.
213. Sly WS, Hu PY: Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401.
214. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996;14:176-186.
215. Burrow CR, Wilson PD: Renal progenitor cells: Problems of definition, isolation and characterization. Exp Nephrol 1994;2:1-12.
216. Ekblom P: Renal development; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology, ed 2. New York, Raven, 1992, pp 475-501.
217. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS: von Hippel-Lindau genemediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58:4957-4962.
218. Bardelli A, Pugliese L, Comoglio PM: 'Invasive-growth' signaling by the Met/HGF receptor: The hereditary renal carcinoma connection. Biochim Biophys Acta 1997;1333:M41-M51.
219. Bardelli A, Ponzetto C, Comoglio PM: Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J Biotechnol 1994;37:109-122.
220. Giordano S, Zhen Z, Medico E, Gaudino G, Galimi F, Comoglio PM: Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci USA 1993;90:649-653.
221. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG, Linehan WM, Klausner RD, Gnarra JR, Van de Woude GF: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factorinduced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-5912.
222. Kanno H, Saljooque F, Yamamoto I, Hattori S, Yao M, Shuin T, U H-S: Role of the von HippelLindau tumor suppressor protein during neuronal differentiation. Cancer Res 2000;60:2820-2824.